Breaking News

Financial Report: AMRI

February 12, 2013

Unaudited revenues up 44% in the quarter

AMRI

4Q Revenues: $67.2 million (+44%)

4Q Earnings: $1.9 million (loss of $24.4 million in 4Q11)

FY Revenues: $226.7 million (+9%)

FY Loss: $3.8 million (loss of $32.3 million FY11)

Comments: Contract revenue in the quarter was $59.1 million, up 50%. Development/Small Scale Manufacturing revenue was $10.4 million, up 41%. Large Scale Manufacturing revenue was $38.1 million, up 69%. Discovery Services revenue was $10.6 million, up 12%. Royalty revenue in the quarter was $8.1 million, up 13%. Loss in 4Q11 was related to charges associated with the company's closure of its Bothell, WA facility. FY12 loss includes asset impairment charges of $6.7 million and restructuring charges of approximately $4.2 million related to the company's realignment of its global Discovery Services platform.
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.